Table 4

Age-stratified analysis of lifetime risk of ovarian cancer

SEER adjusted incidence rateaCarrier prevalenceRelative riskCarrier incidence ratePenetranceb (95% CI)
BRCA1
 20–29 yrs0.00040.01642.40.0101% (0–2%)
 30–39 yrs0.00080.01642.40.0203% (1–7%)
 40–49 yrs0.00170.01990.80.08011% (7–21%)
 50–59 yrs0.00320.00653.00.13223% (16–44%)
 60–69 yrs0.00450.00653.00.18537% (25–71%)
 70–79 yrs0.00580.00653.00.24052% (35–90%)
 80+ yrs0.00570.00653.00.23363% (44–96%)
BRCA2
 20–29 yrs0.00040.0126.50.0020.2% (0–1%)
 30–39 yrs0.00080.0126.50.0050.7% (0–3%)
 40–49 yrs0.00170.01014.90.0233% (1–8%)
 50–59 yrs0.00320.00729.70.08011% (7–21%)
 60–69 yrs0.00450.00729.70.11221% (13–41%)
 70–79 yrs0.00580.00729.70.14532% (20–60%)
 80+ yrs0.00570.00729.70.14142% (26–73%)
  • a The adjusted incidence rates (Ra*) from Table 3<$REFLINK> .

  • b Penetrance is the probability of a mutation carrier developing ovarian cancer by the end of the age interval.